Guideline-directed therapy at discharge in patients with heart failure and atrial fibrillation by 媛뺤꽍誘�
292  Ahn M- S, et al. Heart 2020;106:292–298. doi:10.1136/heartjnl-2019-315240
Original research
Guideline- directed therapy at discharge in patients 
with heart failure and atrial fibrillation
Min- soo ahn   ,1 Byung su Yoo   ,1 Junghan Yoon   ,1 seung- hwan lee   ,1 
Jang Young Kim   ,1 sung gyun ahn   ,1 Young Jin Youn   ,1 Jun- Won lee   ,1 
Jung- Woo son   ,1 hye sim Kim   ,2 Dae ryong Kang   ,2 hyun- Jai cho   ,3 
hae- Young lee   ,4 eun seok Jeon   ,5 seok- Min Kang   ,6 Dong- Ju choi   ,7 
Myeong- chan cho   8 
Heart failure and cardiomyopathies
To cite: ahn M- s, Yoo Bs, 
Yoon J, et al. Heart 
2020;106:292–298.
 ► additional material is 
published online only. To 
view, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136heartjnl- 2019- 315240).
For numbered affiliations see 
end of article.
Correspondence to
Professor Byung su Yoo, 
Department of internal 
Medicine, Yonsei University, 
Wonju college of Medicine, 
Wonju 26426, republic of 
Korea;  yubs@ yonsei. ac. kr
This abstract was presented as 
a poster presentation at ehra 
2019.
received 13 april 2019
revised 8 July 2019
accepted 24 July 2019
Published Online First 
6 september 2019
© author(s) (or their 
employer(s)) 2020. re- use 
permitted under cc BY- nc. no 
commercial re- use. see rights 
and permissions. Published 
by BMJ.
ABSTRACT
Objectives This study evaluated the relationship 
between guideline adherence for recommended therapy 
on discharge and relevant 60- day and 1- year clinical 
outcomes in patients with acute heart failure (hF) with 
reduced ejection fraction and atrial fibrillation (aF).
Methods Of 5625 acute patients with hF in the 
Korean acute heart Failure registry, 986 patients with 
hF and documented aF were analysed. guideline 
adherence scores were calculated for the prescription 
of ace inhibitors, angiotensin receptor blockers, 
β- blockers, mineralocorticoid receptor antagonists and 
anticoagulants.
Results in patients with hF with aF, there was 
a significant trend of reduced 60- day and 1- year 
mortality rates and the composite end point with 
guideline adherence. according to the cox proportion 
hazard model, poor adherence was associated with a 
significantly higher risk of 60- day mortality (hr 4.75; 
95% ci 1.77 to 12.74) and the composite end point 
(hr 2.36; 95% ci 1.33 to 4.18) compared with good 
adherence. Furthermore, poor adherence was associated 
with a significantly higher risk of 1- year mortality 
compared with moderate (hr 1.64; 95% ci 1.15 to 2.33) 
and good adherence (hr 2.34; 95% ci 1.39 to 3.97) 
and with a higher risk of the 1- year composite end point 
compared with good adherence (hr 1.58; 95% ci 1.07 
to 2.33).
Conclusion Better adherence to guidelines was 
associated with better 60- day and 1- year prognoses in 
patients with hF with aF.
InTROduCTIOn
Atrial fibrillation (AF) is common in patients with 
heart failure (HF) because the pathophysiology 
and risk factors for HF and AF are closely associ-
ated.1 Regardless of which comes first, patients with 
concomitant HF and AF have significantly poor 
prognoses.2 Acute HF (AHF) is a life- threatening 
medical condition with a high inpatient mortality 
(typically >4%); however, most cases of morbidity 
and mortality occur after the index hospital 
discharge.3 Therefore, comprehensive strategies 
should focus on factors during hospitalisation and 
also on those during the early recovery period soon 
after discharge to target stressors that contribute to 
patient vulnerability. HF guidelines recommend that 
evidence- based oral disease- modifying HF therapy 
should be started or continued on admission with 
AFH, except in the presence of a contraindica-
tion.4–6 The evidence- based benefits of guideline- 
directed therapy for HF have been documented, 
including reduced ejection fraction (HFrEF) and 
normal sinus rhythm, but there are limited and 
conflicting data regarding the prognostic implica-
tions of guideline- directed therapy for patients with 
acute HFrEF with AF. Thus, this study assessed 
the relationship between guideline adherence on 
discharge and relevant 60- day and 1- year clinical 
outcomes in patients with acute HFrEF with AF.
MeTHOdS
Study population
This study used the registry of the Korean Acute 
Heart Failure (KorAHF) study, a multicentre 
prospective cohort study that enrolled 5,625 
consecutive patients who were hospitalised for 
AHF at 10 tertiary university hospitals between 
March 2011 and February 2014. The patients were 
scheduled for follow- up until the end of 2018. The 
registry included patients with signs or symptoms of 
HF who met at least one of the following criteria: 
(1) lung congestion or (2) objective findings of 
left ventricular (LV) systolic dysfunction or struc-
tural heart disease. Lung congestion was defined 
as ‘congestion’ on chest radiography or as rales 
on physical examination. The study protocol was 
approved by the ethicscommittee of each hospital. 
Detailed information on the study design and the 
results of the KorAHF registry has been provided 
previously.7 From this population, we selected 
patients with HFrEF and AF who had survived 
hospitalisation with 1 year of follow- up data.
Modified guideline adherence score
To assess adherence to guidelines, a modified guide-
line adherence score was calculated. This score was 
adopted and modified from the QUality of Adher-
ence to guideline recommendations for LIFe- saving 
treatment in heart failure surveY (QUALIFY) inter-
national survey.8 A global guideline adherence score 
in QUALIFY was constructed on the basis of physi-
cians’ adherence to guidelines regarding prescription 
of the following classes of medications: ACE inhibi-
tors (ACEIs), angiotensin receptor blockers (ARBs), 
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Figure 1 Flow diagram of patients included in the study from 
theKorAHF. AF, atrial fibrillation.
β- blockers, mineralocorticoid receptor antagonists (MRAs) and 
ivabradine, which are recommended by the American College of 
Cardiology (ACC)/American Heart Association (AHA)/European 
Society of Cardiology (ESC) guidelines for patients with HF with 
normal sinus rhythm, unless contraindicated or not tolerated.4 6 8 
However, ivabradine was excluded from this study because it is only 
indicated for patients with a normal sinus rhythm. Alternatively, 
anticoagulation therapy was included as guideline- recommended 
therapy because patients with HF and AF should generally receive 
anticoagulation therapy to balance the benefit and risk of bleeding 
(using CHA2DS2- VASc and HAS- BLED scores).
9 10 In addition to 
the reduction of stroke and distal embolisation, anticoagulants 
markedly reduce the risk of death; the salutary effect of warfarin 
may be multifactorial.11 The adherence score was the ratio of 
treatment actually prescribed to the treatment that should have 
theoretically been prescribed. The score was calculated for each 
patient by summing the following points: 0 for non- prescription in 
the absence of specified contraindications and 1 point each for the 
use of ACEIs or ARBs, β- blockers, MRAs and oral anticoagulation 
(if indicated). Only guideline- recommended β- blockers, including 
bisoprolol, carvedilol, sustained- release metoprolol succinate 
and nebivolol were scored as adherence to guidelines. Non- 
administration of recommended drugs because of specific contra-
indications or intolerance was scored as adherence to guidelines.8 
Moreover, non- administration of anticoagulation for a CHA2DS2- 
VASc score <2 was scored as adherence. The score ranged from 
0 to 1, and three levels of adherence were defined: good (use of 
all indicated medications; score=1), moderate (use of more than 
half of the indicated medications; 0.5≤score<1) and poor (use of 
<50% of the indicated medications; score<0.5) adherence.8 12
Clinical outcomes
Clinical outcomes after discharge in the KorAHF registry 
included all- cause death, death from HF aggravation and 
rehospitalisation for HF aggravation. The attending physician 
collected follow- up data from the patients and stored them in 
a web- based case report form. The outcome data for subjects 
who were not followed up were ascertained by a telephone inter-
view. In addition, the outcome data for patients who were lost to 
follow- up were ascertained from the National Death Records. All 
clinical events were monitored and verified by a Clinical Event 
Committee, comprising independent experts on HF who did not 
participate in patient enrolment for the study.7 In this study, the 
outcomes were defined as 60- day and 1- year all- cause mortality, 
rehospitalisation because of aggravated HF and a composite end 
point of mortality and HF rehospitalisation.
Statistical analysis
Continuous variables are reported as mean±SD and were 
compared using analysis of variance. Categorical variables are 
presented as frequencies and percentages and were compared using 
the χ2 test. Individual and composite clinical outcomes were anal-
ysed on the basis of time to the first event. Kaplan- Meier survival 
curves were plotted, and the groups were compared using the log- 
rank test. To assess the relationship between outcomes and guide 
adherence, Cox proportional hazards regression models were 
used. The models were adjusted for prespecified baseline covari-
ates, including sex, age, body mass index, history of hypertension, 
history of diabetes mellitus, history of ischaemic heart disease, 
history of chronic obstructive pulmonary disease, type of HF (de 
novo vs acute decompensated HF), New York Heart Association 
functional class, systolic blood pressure, heart rate, creatinine at 
admission and left ventricular ejection fraction (LVEF). Competing 
risk analysis, using the subdistribution hazard model proposed by 
Fine and Gray, was used to examine associations of the guideline 
adherence with HF rehospitalisation by accounting for competing 
risks of death.13 This method adjusts for the potential preclusion 
of the occurrence of the event of interest by another event occur-
ring earlier, the competing event. In all cases, a p value ≤0.05 
was considered statistically significant. Statistical analyses were 
performed using SPSS V.23.0 (IBM, USA) and SAS V.9.4 (SAS, 
Cary, North Carolina, USA).
ReSulTS
Baseline characteristics and medication at discharge of the 
study population
Of the 5625 patients in the KorAHF registry, 4640 were excluded 
because of a normal sinus rhythm, HF with preserved ejection frac-
tion, in- hospital death, need for transplantation, incomplete echo-
cardiographic or electrocardiographic data or incomplete data on 
discharge medication (figure 1). Finally, 986 patients with HF with 
AF were included in this study. The modified guideline adherence 
score was good in 21%, moderate in 64.1% and poor in 14.9% of 
the patients. As expected, the patients had unfavourable clinical char-
acteristics with a lower guideline adherence score. There was a signif-
icant trend towards decreased guideline adherence with increasing 
age. The characteristics of poor guideline adherence were as follows: 
lower body mass index, high proportion of chronic kidney disease, 
lower levels of sodium and haemoglobin and lower proportion of de 
novo HF. The CHA2DS2- VASc score was inversely correlated with 
guideline adherence (3.9±1.7 vs 3.7±1.7 vs 3.2±1.6, p<0.001). 
The morphofunctional parameters measured by echocardiography 
were similar (table 1).
In the poor adherence group, the adherence rates for guideline- 
directed therapies were as follows: 20.4% for use of ACEIs or 
ARBs, 16.3% for β- blockers, 12.2% for MRAs and 25.9% for 
warfarin. The calculated equivalent doses of each medication did 
not significantly differ according to adherence. The prescription 
rates of other medications, including loop diuretics and digitalis, 
were also significantly lower in the poor adherence group (table 2).
Clinical outcomes
In total, 200 (20.3%) patients died and 200 (20.3%) patients were 
rehospitalised during the 1- year follow- up period. The incidences 
of 60- day mortality and the composite end point increased with 
a decrease in guideline adherence (p<0.001). These events most 
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Table 1 Baseline characteristics of patients according to the modified guideline adherence score
Poor (n=147) Moderate (n=632) Good (n=207) P value
Demographic characteristics at admission
  Age, years 72.8±13.1 69.2±12.3 64.3±13.5 <0.001
  Male, % 38.8 39.9 28.5 0.01
  BMI, kg/m2 22.4±3.6 23.1±3.7 24.2±3.9 <0.001
  sBP, mm Hg 126.3±27.1 126.3±27.2 127.1±26.8 0.83
  dBP, mm Hg 76.2±17.9 79.4±18.3 82.2±18.4 0.01
  Pulse rate, beats/min 102.0±29.6 99.2±29.4 97.6±27.7 0.36
  De novo heart failure 57 (38.8) 287 (45.4) 108 (52.2) 0.04
NYHA functional class 0.24
  II, n (%) 17 (11.6) 90 (14.2) 22 (10.6)
  III, n (%) 57 (38.8) 241 (38.1) 96 (46.4)
  IV, n (%) 73 (49.7) 301 (47.6) 89 (43.0)
Comorbidity
  Hypertension, n (%) 78 (53.1) 353 (55.9) 109 (52.7) 0.66
  DM, n (%) 42 (28.6) 197 (31.2) 57 (27.5) 0.56
  IHD, n (%) 29 (19.7) 169 (26.7) 34 (16.7) 0.01
  COPD, n (%) 22 (15.0) 78 (12.3) 16 (7.7) 0.09
  CKD, n (%) 27 (18.4) 80 (12.7) 18 (8.7) 0.03
  CVD, n (%) 29 (19.7) 100 (15.8) 34 (16.4) 0.52
  CHA2DS2- VASc score 3.9±1.7 3.7±1.7 3.2±1.6 <0.001
Aetiology of heart failure 0.01
  IHD, n (%) 46 (31.3) 192 (30.4) 41 (19.8)
  VHD, n (%) 24 (16.3) 82 (13.0) 15 (7.2)
  Cardiomyopathy, n (%) 36 (24.5) 166 (26.3) 79 (38.2)
ECG characteristics at admission
  RBBB 15 (10.2) 37 (5.9) 13 (6.3) 0.16
  LBBB 8 (5.4) 38 (6.0) 8 (3.9) 0.50
  QTc 484.3±57.5 478.0±47.7 484.7±42.2 0.12
Laboratory characteristics at admission
  Na, mmol/L 136.7±5.3 137.3±4.8 138.5±3.6 0.001
  Haemoglobin, g/L 127.2±20.8 129.6±22.8 136.2±23.1 <0.001
  Creatinine, mg/dL 1.39±0.60 1.48±1.36 1.37±1.18 0.48
  BNP, pg/mL 1777.2±1850.7 1342.4±1340.5 1381.6±1090.3 0.14
  Troponin I, mg/mL 2.1±8.0 1.1±6.0 0.3±1.2 0.04
Echocardiographic characteristics
  LVEDV, mL 159.0±80.4 160.6±64.4 171.8±74.1 0.20
  LVESV, mL 114.0±67.3 115.6±50.7 127.1±61.2 0.08
  LVEF, % 26.4±8.4 27.4±8.1 27.2±7.9 0.43
  LA volume index, mL/m2 73.2±30.2 71.8±32.0 77.0±32.3 0.35
Values are presented as numbers (%) or mean±SD, unless otherwise indicated.
BMI, body mass index; BNP, B- type natriuretic peptide; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; DM, diabetes 
mellitus; IHD, ischaemic heart disease; LA, left atrium; LBBB, left bundle branch block; LVEDV, left ventricular end- diastolic volume; LVEF, left ventricular ejection fraction; LVESV, 
left ventricular end- systolic volume; NYHA, New York Heart Association; Na, serum sodium; RBBB, right bundle branch block; VHD, valvular heart disease; dBP, diastolic blood 
pressure; sBP, systolic blood pressure.
frequently occurred in the poor adherence group. There was an 
increased tendency towards 60- day HF rehospitalisation with a 
decrease in guideline adherence, but the difference was not statis-
tically significant. The incidences of 1- year mortality and the 
composite end point increased with a decrease in guideline adher-
ence. However, the tendency for 1- year HF rehospitalisation was 
not different (table 3, figure 2).
effect of guideline adherence on clinical outcomes
After adjusting for covariates in the multivariable Cox model, 
there was a significant trend towards a reduced 60- day 
mortality (p for trend <0.001) and composite end point (p 
for trend=0.002) with guideline adherence (figure 3). Poor 
adherence was associated with a significantly higher risk of 
60- day mortality compared with moderate (HR 2.74; 95% 
CI 1.62 to 4.62) and good adherence (HR 4.75; 95% CI 1.77 
to 12.74). It was associated with a higher risk of the 60- day 
composite end point compared with moderate (HR 1.61; 
95% CI 1.09 to 2.36) and good adherence (HR 2.36; 95% CI 
1.33 to 4.18). Furthermore, there was a significant trend 
towards an increase in 1- year mortality (p for trend=0.001) 
and the composite end point (p for trend=0.02) with guideline 
adherence. Poor adherence was associated with a significantly 
higher risk of 1- year mortality compared with moderate (HR 
1.64; 95% CI 1.15 to 2.33) and good adherence (HR 2.34; 
95% CI 1.39 to 3.97) and with a higher risk of the 1- year 
composite end point compared with good adherence (HR 
1.58; 95% CI 1.07 to 2.33) (figure 3). Similar results were 
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Table 2 Medical therapy at discharge
Poor (n=147) Moderate (n=632) Good (n=207) P value
ACEI or ARB 30 (20.4) 535 (84.7) 207 (100) <0.001
  ACEI 12 (8.2) 247 (39.1) 99 (47.8) <0.001
   Ramipril equivalent dose (mg) 2.3±1.4 2.6±1.8 3.0±2.2 0.29
  ARB 18 (12.2) 251 (39.7) 99 (47.8) <0.001
   Candesartan equivalent dose (mg) 10.2±7.5 9.8±6.7 9.9±6.4 0.75
β- Blocker 24 (16.3) 355 (56.2) 207 (100) <0.001
  Carvedilol equivalent dose (mg) 12.5±11.4 19.3±20.7 16.2±16.8 0.08
MRA 129 (12.2) 367 (58.1) 207 (100) <0.001
  MRA dose at discharge (mg) 24.0±13.2 24.0±13.8 23.4±14.0 0.90
Warfarin 38 (25.9) 362 (57.3) 207 (100) <0.001
Loop diuretics 97 (66.0) 493 (78.0) 180 (87.0) <0.001
Thiazide diuretics 10 (6.8) 38 (6.0) 16 (7.7) 0.21
Amiodarone 21 (14.3) 84 (13.3) 19 (9.2) 0.26
Digitalis 48 (32.7) 347 (54.9) 127 (61.4) <0.001
Values are presented as numbers (%) or mean±SD, unless otherwise indicated.
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonists.
Table 3 Clinical outcomes according to guideline adherence
Poor (n=147) Moderate (n=632) Good (n=207) P value
Sixty- day heart failure rehospitalisation 20 (13.6) 70 (11.1) 16 (7.7) 0.19
Sixty- day mortality 27 (18.4) 40 (6.3) 7 (3.4) <0.001
Sixty- day composite end point 39 (26.5) 104 (16.5) 22 (10.6) <0.001
One- year heart failure rehospitalisation 31 (21.1) 134 (21.2) 35 (16.9) 0.40
One- year mortality 45 (30.6) 129 (20.4) 26 (12.6) <0.001
One- year composite end point 62 (42.2) 223 (35.3) 54 (26.1) 0.005
Values are numbers (%).
observed when mortality was considered a competing risk 
(online supplementary table).
dISCuSSIOn
Our analysis showed that there was a significant trend towards 
reduced 60- day and 1- year mortality rates and the composite 
end point with guideline adherence at discharge in patients with 
acutely decompensated HFrEF with AF. Moreover, poor adher-
ence was associated with a significantly higher risk of 60- day and 
1- year mortality and the composite end point compared with good 
adherence.
Guideline adherence and outcomes in patients with HF with 
AF
The current guideline recommendation is based on clinical 
trials that demonstrated an improvement in clinical outcomes 
of HF. Data regarding the efficacy of ACEIs, ARBs or MRAs 
in decreasing morbidity in patients with HF with concomitant 
AF, especially admitted patients with AHF, are scarce. Moreover, 
a recent analysis on the use of β- blockers in patients with HF 
with AF documented that β- blockers did not reduce mortality in 
patients with HF with AF.14 15 However, their use is still recom-
mended for reducing adverse remodelling in HF.
Several observational studies have explored the association 
between class adherence to guideline- recommended thera-
pies and clinical outcomes in HF.8 12 16 In the QUALIFY study 
that recently reported a large international survey for HF 
(LVEF≤40%), poor adherence was found to be associated with 
significantly higher rates of overall mortality, HF hospitalisation, 
and the composite end point of cardiovascular hospitalisation or 
cardiovascular death at 6 months. However, the survey included 
patients with chronic HF and a stable status, and the prevalence 
of AF was 26.5%. No study has documented the association 
between guideline adherence and outcomes in patients with 
HF and AF. In this study, there was no relationship between HF 
rehospitalisation and guideline adherence. Although the exact 
reason is not clear in this study, there are several explanations 
for the lack of a beneficial effect of guideline- directed therapy 
in patients with HF with AF. First, the negative inotropic effect 
of β-blockers and the potential worsening of haemodynamics 
can lead to increases in HF rehospitalisation.17 The results of 
the Organised Programme to Initiate Lifesaving Treatment in 
Hospitalised Patients With Heart Failure registry showed that 
the use of β- blockers was associated with a lower risk of rehos-
pitalisation. In that registry, mean LVEF was 39.0%.18 In the 
Carvedilol Prospective Randomised Cumulative Survival study, 
which enrolled severe patients with HF with LVED<25%, the 
use of β- blockers was not associated with death or hospitalisa-
tion during the first 8 weeks (HR 0.85; 95% CI 0.67 to 1.07).19 
In this study, the mean LVEF was 27% in the whole patient 
group. The negative inotropic effect of β-blockers can be more 
pronounced in patients with more deteriorated systolic function. 
Second, worsening renal function (WRF) is an important prog-
nostic factor in patients with HF. In a previous study, initiation 
of candesartan led to a reduction in renal function, and WRF 
was associated with worse clinical outcomes, particularly HF 
hospitalisation.20 In another report on KorAHF, the prevalence 
of WRF in HF was 56.9%.21 Although WRF was not evaluated 
in this study, it can be suggested that WRF developed more 
frequently in patients with ACEIs or ARBs, and HF hospitalisa-
tion may have increased in the treatment group. These effects 
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Figure 2 One- year event- free survival according to the guideline adherence score at discharge: (A) heart failure hospitalisation, (B) mortality, (C) 
composite end point.
Figure 3 Forest plot of clinical outcomes of poor guideline adherence compared with good and moderate guideline adherence. The HRs and 95% 
CIs in comparing the clinical outcomes of heart failure rehospitalisation, mortality and the composite end point, adjusted for sex, age, body mass 
index, history of hypertension, history of diabetes mellitus, history of ischaemic heart disease, history of chronic obstructive pulmonary disease, type 
of heart failure (de novo vs acute decompensated heart failure), New York Heart Association functional class, systolic blood pressure, heart rate, 
creatinine at admission and left ventricular ejection fraction.
can offset the beneficial effect on HF hospitalisation. Third, 
the beneficial effect of β- blockers is mediated by reduction of 
the heart rate, and a lower heart rate is associated with better 
outcomes in patients with HF with a normal sinus rhythm. 
However, heart rate does not have the same prognostic signifi-
cance in patients with AF as it does in those with a normal sinus 
rhythm.14 22 Fourth, AF in patients with HF may be a marker of 
a poorer clinical condition, leading to a worse outcome that is 
less modifiable by guideline- directed therapy.23
The ACC/AHA/ESC guidelines recommend each therapy unless 
they are contraindicated or not tolerated.4 6 8 Several methods 
have been developed to estimate adherence to clinical guidelines. 
The performance measures developed by the American College 
of Cardiology Foundation/AHA/American Medical Association- 
Physician Consortium for Performance Improvement is the 
ratio of patients prescribed each medication to patients with LV 
systolic dysfunction and without contraindications for medica-
tion.24 The patients with contraindications or intolerance were 
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Key messages
What is already known on this subject?
 ► There are limited and conflicting data regarding the 
prognostic implications of guideline- directed therapy in 
patients with heart failure (HF) with reduced ejection fraction 
and atrial fibrillation (AF).
What might this study add?
 ► Better adherence to guidelines is associated with better 60- 
day and 1- year prognoses in patients with HF with AF.
How might this impact on clinical practice?
 ► This study suggests that guideline- directed therapy should be 
started in patients with acute HF with AF, similar to that in 
patients with a normal sinus rhythm.
excluded from estimation of guideline adherence. The guideline- 
adherence indicator indicates the proportion of patients whose 
physicians prescribed medication according to the guidelines.12 
Furthermore, non- administration of recommended drugs 
because of specific contraindications or intolerance was scored 
as adherence to guidelines.4 5 The modified guideline adherence 
score in this study strictly assessed whether physicians adhere to 
guideline recommendations for each individual. As shown in a 
previous study, our analysis also showed that a poorer guideline 
adherence was associated with a poorer prognosis in patients 
with AHF with AF, thus indicating that guideline adherence is 
important for patients with AHF with AF.
Study limitations
Several limitations of the present study should be noted. First, 
this was not a randomised controlled trial but a prospective 
cohort study. Thus, the HF therapy in the KorAHF registry 
was not randomly assigned but was entirely dependent on the 
attending physician, which raises the possibility of selection bias. 
Furthermore, there may be a risk- treatment mismatch in the 
guideline- directed therapy. Patients with poor guideline adher-
ence had unfavourable clinical characteristics, but the rates of 
treatment with guideline- directed therapy were low in high- 
risk patients. Hence, patients with poor guideline adherence 
were at a high risk of death. This bias may have influenced the 
prognostic implications of each therapy despite adjustment for 
several variables that could influence prognosis. Second, we did 
not integrate adherence to the target dose of the recommended 
medication into the adherence score because dose escalation to 
the target dose is usually performed during the follow- up period 
after stabilisation. Third, HF therapy may be changed during 
the follow- up period, and this change may influence the clinical 
outcomes (online supplementary figure). However, the purpose 
of this study was to evaluate whether guideline- directed therapy 
at discharge has prognostic implications. Fourth, AF- specific 
information was limited, as AF diagnosis was based on electro-
cardiography at admission or during admission. This may have 
led to underestimation of AF, as some patients could have had a 
sinus rhythm during baseline electrocardiography and may have 
developed (episodes of) AF during follow- up.
COnCluSIOn
Our study showed that a higher level of adherence to guide-
lines was associated with better 60- day and 1- year prognoses in 
patients with HF with AF. However, there is a clear unmet need 
for patients with HF and AF, given the limited treatment options 
for this important population. Further investigations are required 
for the development of optimal therapeutic options for this patient 
subgroup.
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